Form 4: Kura Oncology Director Helen Collins Receives Stock Options

Director Helen Collins was granted an option to purchase 35,000 shares of Kura Oncology common stock at an exercise price of $8.77.

Summary

• Director Helen Collins received a grant of 35,000 stock options on June 4, 2026.
• The options have an exercise price of $8.77 per share.
• The options are set to expire on June 3, 2036.
• The grant vests in full on the one-year anniversary of the grant date.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine regulatory disclosure regarding director compensation with no immediate impact on company operations or financial health.

Positives

• Alignment of director interests with long-term shareholder value through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders upon exercise.

Risks

• Market volatility affecting the value of the underlying common stock relative to the $8.77 exercise price.

Future Outlook

The options vest in full on June 4, 2027, providing the director with the right to purchase shares at the set strike price until expiration in 2036.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to incentivize long-term oversight and strategic alignment.

Comparison to Industry Standards

• The grant of stock options to non-employee directors is consistent with standard corporate governance practices for mid-cap oncology firms.
• Vesting schedules of one year are common for director equity compensation in the life sciences industry.

Stakeholder Impact

• Minor potential dilution for shareholders upon future exercise of options.

Next Steps

• Vesting of the 35,000 options on June 4, 2027.

Key Dates

Keywords

Kura Oncology, KURA, Form 4, Insider Trading, Stock Options, Director Compensation